# US 2015/0104477 A1 · Ubiquitinylated proteins

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0104477 A1
- Document ID: US20150104477A1
- Status: Published application
- Kind: A1
- Application number: 14/512,322
- Filed: 2014-10-10
- Published: 2015-04-16
- Earliest claimed: 2013-10-11
- Assignees: UbiVac, LLC; Providence Health & Science—Oregon
- Inventors: Christopher Twitty; Erik LeShane; Bernard Fox; Hong-Ming Hu; Guangjie Yu
- Web page: https://patentgrep.com/patent/US20150104477A1

## CPC

- A61K 39/0011: {Cancer antigens}
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 35/00: Antineoplastic agents
- A61P 37/02: Immunomodulators
- A61P 37/04: Immunostimulants
- C12P 21/00: Preparation of peptides or proteins (single cell protein C12N1/00)
- A61K 2039/5154: {Antigen presenting cells [APCs], e.g. dendritic cells or macrophages}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12P: FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE {(brewing of beer C12C; producing vinegar C12J; producing specific peptides or proteins C07K; producing enzymes C12N9/00; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; measuring or testing processes involving enzymes or microorganisms C12Q; measuring or testing processes involving nucleic acid amplification reactions C12Q1/6844; fermentation processes to form a food composition, A21 or A23; compounds in general, see the relevant compound class, e.g. C01, C07)}

## Abstract

A method of inducing a specific immune response in a mammal, comprising: providing a first composition comprising isolated ubiquitinylated proteins in solution in the absence of membrane bound organelles, the isolated ubiquitinylated proteins comprising one or more specific antigens, and further comprising a threshold quantity of polyubiquitinylated short-lived proteins and polyubiquitinylated defective ribosomal products. The isolated ubiquitinylated proteins are affinity-purified from tumor-derived cells grown in culture, the tumor-derived cells being inhibited from degrading ubiquitinylated proteins via the proteasome while being grown in culture. In this way, highly immunogenic short-lived proteins and defective ribosomal products may be loaded onto dendritic cells for cross-presentation and priming of antigen-specific T cells restricted by either classical or non-classical MHC.

## Claims

### Claim 1

A composition configured to induce a specific immune response in a mammal, comprising:
isolated ubiquitinylated proteins in solution in absence of membrane bound organelles, the isolated ubiquitinylated proteins containing one or more specific antigens, and further containing a threshold quantity of polyubiquitinylated short-lived proteins and polyubiquitinylated defective ribosomal products.

### Claim 2 (depends on 1)

The composition of claim 1, wherein the isolated ubiquitinylated proteins are affinity-purified from tumor-derived cells grown in culture.

### Claim 3 (depends on 2)

The composition of claim 2, wherein the tumor-derived cells are inhibited from degrading ubiquitinylated proteins via a proteasome while being grown in culture.

### Claim 4 (depends on 2)

The composition of claim 2, wherein the tumor-derived cells are culture cells derived from a mammalian.

### Claim 5 (depends on 4)

The composition of claim 4, wherein the tumor-derived cells are engineered to express one or more specific antigens not endogenous to the tumor-derived cells.

### Claim 6 (depends on 5)

The composition of claim 5, wherein the one or more specific antigens not endogenous to the tumor-derived cells include a viral antigen.

### Claim 7 (depends on 5)

The composition of claim 5, wherein the one or more specific antigens not endogenous to the tumor-derived cells include a bacterial antigen.

### Claim 8

A method for producing an immunogenic reagent, comprising:
inhibiting proteasomal degradation of ubiquitinylated proteins in tumor-derived cells growing in culture; and
isolating ubiquitinylated proteins in absence of membrane bound organelles from the tumor-derived cells grown in culture, the isolated ubiquitinylated proteins containing one or more specific antigens, and further containing a threshold quantity of polyubiquitinylated short-lived proteins and polyubiquitinylated defective ribosomal products.

### Claim 9 (depends on 8)

The method of claim 8, further comprising:
lysing the tumor cells;
affinity-purifying ubiquitinylated protein from a resulting cell lysate with a recombinant polyubiquitin binding peptide; and
eluting the ubiquitinylated protein from the recombinant polyubiquitin binding peptide.

### Claim 10 (depends on 8)

The method of claim 8, wherein the tumor-derived cells are engineered to express one or more specific antigens not endogenously expressed by the tumor-derived cells.

### Claim 11 (depends on 10)

The method of claim 10, wherein the one or more specific antigens include a viral antigen.

### Claim 12 (depends on 11)

The method of claim 11, wherein the one or more specific antigens include a bacterial antigen.

### Claim 13 (depends on 9)

The method of claim 9, wherein the tumor-derived cells are primary culture cells derived from a tumor in a mammal.

### Claim 14

A method of inducing a specific immune response in a mammal, comprising:
providing a first composition comprising isolated ubiquitinylated proteins in solution, the isolated ubiquitinylated proteins containing one or more specific antigens, and further containing a threshold quantity of polyubiquitinylated short-lived proteins and polyubiquitinylated defective ribosomal products; and
cross-presenting the one or more specific antigens to T cells.

### Claim 15 (depends on 14)

The method of claim 14, further comprising:
loading dendritic cells with the first composition in vitro to generate loaded dendritic cells; and
cross-presenting antigen from the loaded dendritic cells to T cells.

### Claim 16 (depends on 15)

The method of claim 15, wherein antigen is cross-presented from the loaded dendritic cells to T cells in vivo.

### Claim 17 (depends on 14)

The method of claim 14, wherein the first composition is injected into the mammal sub-cutaneously.

### Claim 18 (depends on 14)

The method of claim 14, wherein the first composition is injected into the mammal after a duration following an injection of a second composition capable of inducing a specific immune response in the mammal.

### Claim 19 (depends on 18)

The method of claim 18, where the second composition is an allogeneic autophagosome-enriched composition.

### Claim 20 (depends on 14)

The method of claim 14, where the specific immune response targets classical and/or non-classical MHC restricted antigens.
